Vioxx Successor Arcoxia May Have Similar Heart Attack Risks
Arcoxia, a new experimental painkiller Merck & Co hope will become the successor of Vioxx, which was taken off the market because of its heart attack risks, may have similar risks, say scientists who looked at 23 clinical trials comparing several painkillers.You can read about this new report in JAMA (the Journal of the American Medical Association). [click link for full article]
Can Gleevec Help Patients With Rheumatoid Arthritis?
Imatinib mesylate (Gleevec; Novartis) is often the treatment of choice for individuals with either chronic myelogenous leukemia or gastrointestinal stromal tumors. [click link for full article]
